Saving Beta-Cells, Improving Lives
We develop a novel therapy to reverse the progression of early-stage type 1 diabetes and reduce insulin dependency.
From wildcrafting
to bench-to-bedside development.
Dunica was founded by Daniella Givon, a clinical herbalist and entrepreneur whose daughter was diagnosed with type T1 diabetes at the age of seven years. They were quickly familiarized with the struggle of managing the disease, juggling a strict diet, blood-sugar monitoring, and multiple insulin injections taken day and night.
What makes our therapy unique?
Sustainable
Source
Formulated from the next generation of phytochemicals
Small-Molecule
Structure
Enhanced efficacy through better tissue permeability
Immunomodulating
Therapy
Better safety profile and reduced risk of inflammation
Designed for Oral Consumption
Improved patient experience - No injections needed
Why do experts support our mission?
"DUN T1 seems to be the ideal product to improve the future treatment of Type 1 Diabetes."
Dr. Ulrike Hostalek, Executive Medical Director Head of GMA MU CM&E
Milestons to date
2019
Establishment, In vivo-preclinical safety and efficacy research, F&F fundraising
2020
Stabilizing a raw material source - Domestication of selected botanical strain
2021
Finalization of pre-clinical Proof of Concept, expanding research team
2022
Granted 2 research grants from the pharmaceutical company (Germany)
2023
Mechanism in-vitro study, Granted research grant from the pharmaceutical company
2024
Finalizing development process
